The main purpose of this study is to test the safety, tolerability, maximum tolerated dose,
and effectiveness of bevacizumab in combination with chemotherapy and radiation therapy.
Because bevacizumab is not considered standard therapy for sarcomas, it can only be given to
subjects with sarcoma who are enrolled in this research study and may only be administered
under the direction of doctors who are investigators in this research study.
This study is being done because sarcomas can recur after surgical resection (surgery for
removal of the tumor), radiation therapy and chemotherapy. This recurrence can occur in the
same location as the original tumor or in distant sites such as the lung. Thus better
treatments are needed.
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of
an investigational drug, combination of drugs, or combination of drugs with radiation. Phase
I studies also try to define the appropriate dose of the investigational drug to use for
further studies. "Investigational" means that the combination of drugs and radiation is still
being studied and that research doctors are trying to find out more about it. It also means
that the FDA has not approved bevacizumab with doxorubicin and radiation for your type of
cancer.